Pharmaceutical
Medical
Health
Abbott
$79.969876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$79.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.13 (1.43%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Abbott and other stocks, options, ETFs, and crypto commission-free!
About
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. Read More The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Employees
103,000
Headquarters
Abbott Park, Illinois
Founded
1888
Market Cap
138.40B
Price-Earnings Ratio
60.14
Dividend Yield
1.60
Average Volume
6.08M
High Today
$80.25
Low Today
$79.02
Open Price
$79.18
Volume
1.88M
52 Week High
$80.25
52 Week Low
$56.81
Collections
Pharmaceutical
Medical
Health
Medical Devices
Healthcare
Manufacturing
Technology
US
News
Yahoo Finance15h
What Makes Abbott (ABT) a New Buy Stock
Abbott (ABT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zac...
Yahoo Finance15h
Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results
Abbott Lifesciences ABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial.
Seeking Alpha18h
Abbott's Alinity m CE Mark'd
Abbott (NYSE:ABT) announces that its Alinity m molecular diagnostic system is now CE Mark certified. Initial assays include HIV-1, hepatitis B and C viruses, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium and high-risk HPV. The product is not approved in the U.S....
Price Paid on Robinhood
28% Higher
Right Now
52 Week Low
$56.81
Average Price Paid
$62.41
52 Week High
$80.25
Earnings
$0.58
$0.66
$0.73
$0.81
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 17, Pre-Market